The launch of a new product development lab at Biovac marks a major step forward for South Africa's vaccine production capabilities. Announced on November 7, 2025, by Deputy Minister Dr. Nomalungelo Gina, the lab is poised to allow South Africa to produce vaccines locally for the first time, moving beyond just finishing and packaging imported ingredients. This development is expected to improve access to vaccines, reduce costs, and build local expertise, especially for pressing health concerns like TB and HIV.
Biovac’s new facility in Cape Town will produce vaccines from start to finish, including the development of active ingredients, a shift that could help combat diseases like malaria and diarrhoea. The lab is equipped with advanced mRNA technology, which has been critical in the fight against COVID-19, and will allow South Africa to develop vaccines tailored to local needs. The initiative aligns with Africa’s broader goal of producing 60% of its vaccines by 2040, reducing reliance on imports and ensuring quicker responses to health crises.
Backed by significant funding from the Bill & Melinda Gates Foundation and local partners like the Industrial Development Corporation, the lab will not only strengthen Africa’s vaccine manufacturing but also create high-skilled job opportunities. With this innovation, South Africa is positioning itself as a leader in global health, offering a sustainable solution to the continent's health challenges and contributing to the global health landscape.
Biovac’s new facility in Cape Town will produce vaccines from start to finish, including the development of active ingredients, a shift that could help combat diseases like malaria and diarrhoea. The lab is equipped with advanced mRNA technology, which has been critical in the fight against COVID-19, and will allow South Africa to develop vaccines tailored to local needs. The initiative aligns with Africa’s broader goal of producing 60% of its vaccines by 2040, reducing reliance on imports and ensuring quicker responses to health crises.
Backed by significant funding from the Bill & Melinda Gates Foundation and local partners like the Industrial Development Corporation, the lab will not only strengthen Africa’s vaccine manufacturing but also create high-skilled job opportunities. With this innovation, South Africa is positioning itself as a leader in global health, offering a sustainable solution to the continent's health challenges and contributing to the global health landscape.
